Xiao Guixiu, Xu Zihan, Luo Feng
Lung Cancer Center, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.
Front Pharmacol. 2023 Jan 20;13:1107329. doi: 10.3389/fphar.2022.1107329. eCollection 2022.
Cancer therapies have made tremendous progress in the last decade, but monotherapy still has apparent limitations and lacks therapeutic efficacy. Thus, the simultaneous administration of multiple drugs has been widely explored and has shown better outcomes. Exosomes, deriving from almost all living cells, are natural nanocarriers designed to deliver drugs to tumor sites. Therefore, combinational antitumor therapies based on exosomes, such as engineered exosomes and different combinations of chemotherapeutic agents, therapeutic nucleic acids, photosensitizers, immunotherapy and phytochemicals, have considerable prospects and potential for clinical translation. Here, we summarize current strategies of cancer combination therapy in exosomes and propose opportunities and challenges in the future.
在过去十年中,癌症治疗取得了巨大进展,但单一疗法仍存在明显局限性且缺乏治疗效果。因此,多种药物的联合给药已得到广泛探索,并显示出更好的疗效。外泌体几乎来源于所有活细胞,是一种天然的纳米载体,旨在将药物递送至肿瘤部位。因此,基于外泌体的联合抗肿瘤疗法,如工程化外泌体以及化疗药物、治疗性核酸、光敏剂、免疫疗法和植物化学物质的不同组合,具有相当大的临床转化前景和潜力。在此,我们总结了外泌体中癌症联合治疗的当前策略,并提出了未来的机遇和挑战。